RBA Wealth Management LLC lessened its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 5.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 63,308 shares of the medical equipment provider's stock after selling 3,512 shares during the quarter. Boston Scientific makes up about 2.5% of RBA Wealth Management LLC's portfolio, making the stock its 9th biggest position. RBA Wealth Management LLC's holdings in Boston Scientific were worth $6,800,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Boston Scientific by 17.5% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 6,325 shares of the medical equipment provider's stock worth $638,000 after purchasing an additional 940 shares in the last quarter. Versant Capital Management Inc lifted its holdings in Boston Scientific by 134.9% during the 1st quarter. Versant Capital Management Inc now owns 5,435 shares of the medical equipment provider's stock valued at $548,000 after buying an additional 3,121 shares in the last quarter. Moody National Bank Trust Division increased its position in Boston Scientific by 34.8% during the 1st quarter. Moody National Bank Trust Division now owns 3,756 shares of the medical equipment provider's stock valued at $379,000 after buying an additional 970 shares in the last quarter. Finally, AdvisorNet Financial Inc increased its holdings in shares of Boston Scientific by 18.4% during the 1st quarter. AdvisorNet Financial Inc now owns 5,086 shares of the medical equipment provider's stock valued at $513,000 after purchasing an additional 791 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.
Boston Scientific Stock Performance
BSX stock opened at $98.20 on Friday. The firm has a 50-day simple moving average of $103.79 and a two-hundred day simple moving average of $102.11. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a market cap of $145.51 billion, a price-to-earnings ratio of 58.45, a PEG ratio of 2.36 and a beta of 0.65.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the company posted $0.62 EPS. The business's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.
Insider Activity
In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $18,397,457 over the last quarter. Insiders own 0.50% of the company's stock.
Analyst Ratings Changes
A number of research firms have weighed in on BSX. Leerink Partners assumed coverage on shares of Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Raymond James Financial boosted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Needham & Company LLC reissued a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a report on Friday, September 19th. BTIG Research reiterated a "buy" rating and issued a $127.00 price target on shares of Boston Scientific in a research note on Tuesday, September 23rd. Finally, Robert W. Baird raised their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $118.17.
Read Our Latest Stock Analysis on BSX
Boston Scientific Profile
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
